CTRI/2024/12/078535尚未招募不适用
100 Day Mortality In Advanced Solid Malignancies- Real World Experience In A Tertiary Cancer Centre From South India.
未提供1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2025年1月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- TO DETERMINE THE 100 DAY MORTALITY
研究概览
简要总结
AIM-To determine the 100 day mortality in palliative intent patients? And what are the prognostic factors affecting it? -Key findings
Hundred day mortality was 16%. In this study subgroup analysis showed neutrophil lymphocyte ratio (p=0.04) and performance status (p=0.02) are the significant factors associated 100 day mortality.
-Impact.
Assessing the 100 day mortality validates the clinical decision taken in a department / an institute. Based on this necessary action can be taken to improve the outcome and quality of care.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •ïƒ˜Performance status 1-3 ECOG Age > 18 years Solid cancers Stage IV Planned for palliative sytemic treatment.
排除标准
- •ïƒ˜ Patient not eligible and not willing for systemic therapy.
结局指标
主要结局
TO DETERMINE THE 100 DAY MORTALITY
时间窗: MORTALITY STATUS ON DAY 100 FROM THE START OF FIRST CYCLE
次要结局
- TO STUDY FACTORS AFFECTING 100 DAY MORTALITY(DATA COLLECTED BEFORE THE START OF TREATMENT LIKE AGE, NLR, PS, HEMOGLOBIN, ALBUMIN)
研究者
DR SHASHIDHAR V K
VYDEHI INSTITUTE OF MEDICAL SCIENCES & RESEARCH CENTER
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
To assess blood markers to predict terminal disease in patients suffering from advanced cancers.CTRI/2025/11/097425Rakesh Garg225
尚未招募
不适用
Survival Outcomes in Advanced Solid Cancer Patients with Low Serum Creatinine Referred for Palliative Care: A Prospective Observational Study.CTRI/2025/01/079414Tata Memorial Hospital120
尚未招募
不适用
To study the impact of discussions of imaging with radiologists and palliative medicine physicians on the Quality of Life in Patients with advanced malignancy receiving supportive care.CTRI/2026/02/103940DR BRA INSTITUTE ROTARY CANCER HOSPITAL369
招募中
1 期
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combination with checkpoint inhibitor2023-506854-19-00Immatics Biotechnologies GmbH95
招募中
2 期
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesNCT07415031Mirati Therapeutics Inc.170